This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes.
The study is looking at:
* What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well
Body Mass Index (BMI) ≥30.0 kg/m² to <45.0 kg/m² at screening OR
BMI ≥27.0 kg/m² at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary Artery Disease (CAD), Heart failure, established cerebrovascular disease as described in the protocol
Previous or current diagnosis of Type 1 or Type 2 diabetes at screening
Change in body weight >5 kg within approximately 3 months before screening as described in the protocol
Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions as described in the protocol
History of acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones
Parallel
Olatorepatide
DrugAdministered per the protocol
Placebo
DrugAdministered per the protocol
6
Treatment groupsSee each treatment group below.
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Percent change in body weight
Olatorepatide concentrations
Occurrence of Anti-Drug Antibody (ADA) to olatorepatide
Magnitude of ADA to olatorepatide
Click on the lead sponsor to view all of their trials.
